Beijing Beilu Pharmaceutical Hits Day High with 6.31% Surge

Beijing Beilu Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 6.31% on March 5, 2026. The stock reached an intraday high of CNY 10.20, showcasing its strong market activity. This performance stands in contrast to the China Shanghai Composite, which declined by 1.26% on the same day. Over the past year, Beijing Beilu has demonstrated impressive growth, with a return of 51.12%, significantly outperforming the China Shanghai Composite's 22.49%. Year-to-date, the stock has risen by 27.33%, further highlighting its robust market position. The company's net sales for the first nine months reached CNY 872.68 million, reflecting a growth rate of 21.13%. Additionally, the net profit for the half-year period was reported at CNY 25.38 million. Despite a high price-to-earnings ratio of 309.00 and a price-to-book value of 1.81, Beijing Beilu maintains a competitive edge in the pharmaceuticals and biotechnology sector. The company’s operating cash flow reached its highest at CNY 176.47 million, indicating solid financial health. Overall, Beijing Beilu Pharmaceutical Co., Ltd. continues to show strong performance metrics in a challenging market environment.